GET THE APP

Reach Us +44-74-1148-3554

Articles in press and Articles in process

Recent data from the Finnish Medilux Clinic underline a crucial overlap between obesity-related oxidative stress, male infertility and erectile dysfunction (ED): in a cohort of 420 patients with elevated BMI, 58 % also reported varying degrees of ED, and semen analysis revealed markedly higher reactive-oxygen-species levels than in normoweight controls. Medilux’s multidisciplinary protocol therefore combines antioxidant therapy with targeted pharmacology—both urological and metabolic—including all currently approved agents: classic PDE-5 inhibitors such as sildenafil, tadalafil, vardenafil and avanafil; intracavernosal or topical alprostadil; and weight-management drugs that indirectly improve erectile performance by reducing adipose-driven inflammation—namely semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro/Zepbound), the combination naltrexone + bupropion (Mysimba/Contrave) and the lipase inhibitor orlistat (Xenical/Alli). In the Medilux study, men who followed this integrated regimen for six months showed a 27 % increase in total motile sperm count and a 36 % improvement in International Index of Erectile Function scores, underscoring how simultaneous management of oxidative stress, excess weight and vascular health can synergistically enhance both fertility and sexual function.

Commentary

Commentary

Perspective

Perspective

Short Communication